Professor Spencer Collis
School of Medicine and Population Health
Professor of Genome Stability
+44 114 215 9043
Full contact details
School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Profile
-
For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk
1994 - 1997
BSc (Hons): Biochemistry, UMIST1997 - 2000
PhD: Oncology, CRUK Paterson Institute for Cancer Research2001 - 2004
Post-Doc: Prof. Theodore DeWeese laboratory, Johns Hopkins University2004 - 2009
Post-Doc: Dr Simon Boulton laboratory, Clare Hall Laboratories, CRUK London Research Institute2009 - 2013
Group leader: Institute for Cancer Studies, TV2013 - 2015
Senior Lecturer: Academic unit of Molecular Oncology, Department of Oncology, TV2016 - 2024
Reader: Academic unit of Molecular Oncology, Department of Oncology, TV2024 - present
Professor: Division of Clinical Medicine, TVCurrent PhD Opportunities:
- Research interests
-
I am a molecular and cancer cell biologist with nearly 30 years of experience in the field of DNA damage/repair and genome stability mechanisms. In collaboration with both clinicians and industry partners, my laboratory studies these processes in relation to cancer biology and potential therapeutic strategies, with a particular emphasis on glioblastomas.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . JBMR Plus, 9(10).
- . Cell Reports, 44(3), 115361-115361.
- . Cell Death & Disease, 15(12).
- . F1000Research, 13.
- . Cancers, 16(5).
- . F1000research, 12.
- . British Journal of Cancer, 129(11), 1829-1840.
- . Expert Reviews in Molecular Medicine, 24.
- . Molecular Oncology, 16(1), 11-41.
- . Cancers, 13(5).
- . Br J Cancer, 124(4), 697-709.
- . Sci Adv, 6(28), eaba5974.
- . Cancers (Basel), 11(3).
- . Oncotarget, 9(50), 29508-29524.
- . Sci Rep, 6, 35548.
- . Nucleic Acids Res, 44(18), 8772-8785.
- . Cell Rep, 16(10), 2565-2575.
- . Cilia, 5, 19.
- . Cell Cycle, 13(21), 3450-3459.
- . Oncotarget, 5(15), 6414-6424.
- . J Cell Sci, 127(Pt 13), 2910-2919.
- . J Cell Sci, 125(Pt 20), 4770-4779.
All publications
Journal articles
- . Neuro-Oncology, 27(Supplement_3), iii130-iii130.
- . Neuro-Oncology, 27(Supplement_2), ii29-ii29.
- . JBMR Plus, 9(10).
- . Cell Reports, 44(3), 115361-115361.
- . Neuro-Oncology Practice, 12(4), 585-599.
- . Cell Death & Disease, 15(12).
- . Neuro-Oncology, 26(Supplement_8), viii117-viii118.
- . Neuro-Oncology, 26(Supplement_8), viii118-viii118.
- . F1000Research, 13.
- . Cancers, 16(5).
- . Neuro-Oncology, 26(4), 625-639.
- . F1000research, 12.
- . British Journal of Cancer, 129(11), 1829-1840.
- . Neuro-Oncology, 25(Supplement_3), iii14-iii14.
- . Nanotheranostics, 7(1), 102-116.
- . Neuro-Oncology, 24(Supplement_7), vii31-vii31.
- . Neuro-Oncology, 24(Supplement_7), vii93-vii93.
- . Expert Reviews in Molecular Medicine, 24.
- . Molecular Oncology, 16(1), 11-41.
- . BRITISH JOURNAL OF CANCER, 125(4), 623-623.
- . British Journal of Surgery, 108(Supplement_1).
- . Cancers, 13(5).
- . Br J Cancer, 124(4), 697-709.
- . Sci Adv, 6(28), eaba5974.
- . J Cell Sci, 133(9).
- . Neuro-Oncology, 21(Supplement_6), vi209-vi209.
- . Neuro-Oncology, 21(Supplement_6), vi271-vi271.
- . Cancers (Basel), 11(3).
- NOVEL DRUG TARGETS TO AUGMENT TEMOZOLOMIDE SENSITIVITY IN HIGH-GRADE BRAIN TUMOURS. NEURO-ONCOLOGY, 20, 346-346.
- . Neuro-Oncology, 20(suppl_3), iii297-iii297.
- . Oncotarget, 9(50), 29508-29524.
- . Sci Rep, 6, 35548.
- . Nucleic Acids Res, 44(18), 8772-8785.
- . Cell Rep, 16(10), 2565-2575.
- . Cilia, 5, 19.
- . Neuro-Oncology, 17(suppl 8), viii20.1-viii20.
- . Cell Cycle, 13(21), 3450-3459.
- . Oncotarget, 5(15), 6414-6424.
- . J Cell Sci, 127(Pt 13), 2910-2919.
- . Development, 140(2), e207-e207.
- . J Cell Sci, 125(Pt 20), 4770-4779.
- . Mol Cell, 39(6), 839-850.
- . Mol Cell, 39(1), 25-35.
- . PLoS One, 5(6), e11208.
- . EMBO J, 29(4), 703-705.
- . Cell Cycle, 8(8), 1133-1137.
- . Mol Cell Biol, 28(5), 1470-1479.
- . Mol Cell, 32(3), 313-324.
- . Cell, 135(2), 261-271.
- . Int J Radiat Oncol Biol Phys, 70(5), 1310-1318.
- . Int J Radiat Oncol Biol Phys, 69(4), 1262-1271.
- . Chromosoma, 116(4), 331-339.
- . Nat Cell Biol, 9(4), 391-401.
- . CANCER RES, 66(17), 8814-8821.
- . DNA Repair (Amst), 5(11), 1398-1406.
- . Oncogene, 24(6), 949-961.
- . J Biol Chem, 279(48), 49624-49632.
- . Cancer Metastasis Rev, 23(3-4), 277-292.
- . Radiat Res, 162(1), 48-55.
- . Radiat Res, 161(3), 247-255.
- . World J Urol, 21(4), 275-289.
- Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors.. Cancer Res, 63(7), 1550-1554.
- Expression of the DNA-PK binding protein E4-34K fails to confer radiation sensitivity to mammalian cells.. Int J Radiat Biol, 79(1), 53-60.
- . Nucleic Acids Res, 30(2), E1.
- . Nucleic Acids Res, 29(7), 1534-1538.
- . F1000Research, 12, 954-954.
Book chapters
- , Targeted Radionuclide Tumor Therapy Biological Aspects (pp. 329-347).
- Molecular targeting of DNA repair: A means to improve therapeutic index, New Research on DNA Repair (pp. 1-37).
Conference proceedings
- Addition of ATM Inhibitors to Radium223 Reduces Prostate Cancer Bone Metastases In Vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 214-215)
- . Neuro-Oncology, Vol. 25(Supplement_3) (pp iii5-iii6)
- GENERATION AND CHARACTERISATION OF A LIVING BIOBANK OF POST-SURGICAL RESIDUAL GLIOBLASTOMA TO IDENTIFY NOVEL THERAPEUTIC TARGETS.. NEURO-ONCOLOGY, Vol. 24 (pp 31-31)
- COMBINING TUMOUR TREATING FIELDS WITH THERAPEUTIC DNA DAMAGE RESPONSE INHIBITORS TO INCREASE POTENCY IN HIGH-GRADE GLIOBLASTOMAS USING CLINICALLY RELEVANT EX-VIVO GLIOMA STEM CELL MODELS.. NEURO-ONCOLOGY, Vol. 24 (pp 93-93)
- . Brain Tumor Research and Treatment, Vol. 10(Suppl) (pp s240). Seoul, Korea, 24 March 2022 - 24 March 2022.
- . WFNOS 2022 Abstract Book (pp S219-S219), 24 March 2022 - 27 March 2022.
- . WFNOS 2022 Abstract Book (pp S253-S253), 24 March 2022 - 27 March 2022.
- . WFNOS 2022 Abstract Book (pp S65-S65), 24 March 2022 - 27 March 2022.
- . WFNOS 2022 Abstract Book (pp S251-S251), 24 March 2022 - 27 March 2022.
- . WFNOS 2022 Abstract Book (pp S227-1), 24 March 2022 - 27 March 2022.
- EX-VIVO 3-DIMENSIONAL MODELS OF POST-SURGICAL RESIDUAL DISEASE IN HUMAN GLIOBLASTOMA. NEURO-ONCOLOGY, Vol. 21 (pp 271-271)
- FA-BASED COMBINATIONS TO TARGET THE DNA DAMAGE RESPONSE IN GLIOBLASTOMA. NEURO-ONCOLOGY, Vol. 20 (pp 358-358)
- PRECLINICAL EVALUATION OF COMBINATIONS TARGETING THE DNA DAMAGE RESPONSE IN 2D AND 3D MODELS OF GLIOBLASTOMA STEM CELLS. NEURO-ONCOLOGY, Vol. 20 (pp 297-297)
- Improving the Efficacy of Pulsed Radiation Therapy Using DNA Repair Inhibitors: A Preclinical Study. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol. 96(2) (pp E566-E567). Boston, Massachusetts, USA
- . European Journal of Cancer, Vol. 61 (pp S35-S35)
- IDENTIFICATION OF NOVEL SMALL MOLECULE INHIBITORS OF THE FANCONI ANAEMIA DNA REPAIR PATHWAY AS A MEANS TO SENSITISES GLIOBLASTOMAS TO CHEMOTHERAPEUTIC AGENTS. NEURO-ONCOLOGY, Vol. 17 (pp 20-20)
- Optimization of siRNA-transgene expression in adenoviral vector systems for radiation sensitizing strategies. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol. 69(3) (pp S595-S596)
- . BREAST CANCER RESEARCH, Vol. 8 (pp S6-S6)
Preprints
- , Springer Science and Business Media LLC.
- , Springer Science and Business Media LLC.
- , Cold Spring Harbor Laboratory.
- .
- Research group
-
Research Group
- Dr. Cerys Evens (Postdoctoral Research Associate)
- Dr. Katie Myers (Research Assistant/Lab Manager)
- Dr. Callum Jones (Postdoctoral Research Associate)
- Dr. Sophie Williams (Clinical PhD Fellow)
- Kelsey Wosnitzka (PhD student with Mr. Ola Rominiyi)
- Rebecca Livesey (PhD student with Prof. Fred Claeyssens)
- Tegan Torpey (PhD student with Mr. Ola Rominiyi and Prof. Fred Claeyssens)
- Teaching interests
-
M.Sc. Molecular Medicine
M.Sc. Translational Oncology
MSc Genomic Medicine